By Al Barbarino ( April 29, 2026, 1:21 PM EDT) -- Chiesi Group said Wednesday it will acquire KalVista Pharmaceuticals in a deal valued at about $1.9 billion, expanding the Italian biopharmaceutical company's rare disease portfolio with a newly approved treatment for a rare hereditary swelling disorder. ...
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.